|
gptkbp:instanceOf
|
gptkb:long-acting_insulin
|
|
gptkbp:approvalYear
|
2005
|
|
gptkbp:ATCCode
|
A10AE05
|
|
gptkbp:brand
|
gptkb:Levemir
|
|
gptkbp:CASNumber
|
169148-63-4
|
|
gptkbp:contraindication
|
hypersensitivity to insulin detemir
|
|
gptkbp:developer
|
gptkb:Novo_Nordisk
|
|
gptkbp:drugBank_ID
|
DB01309
|
|
gptkbp:duration
|
up to 24 hours
|
|
gptkbp:eliminationHalfLife
|
5-7 hours
|
|
gptkbp:form
|
solution for injection
|
|
gptkbp:hasMolecularFormula
|
C267H402N64O76S6
|
|
gptkbp:KEGGID
|
D04566
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
insulin receptor agonist
|
|
gptkbp:metabolism
|
gptkb:kidney
liver
|
|
gptkbp:notable_for
|
lower risk of nocturnal hypoglycemia than NPH insulin
less weight gain than NPH insulin
|
|
gptkbp:origin
|
genetically engineered yeast
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:prescribes
|
adults
children (age 2 and older)
|
|
gptkbp:prescriptionForm
|
gptkb:cartoonist
vial
|
|
gptkbp:prescriptionRequired
|
https://www.novo-pi.com/levemir.pdf
|
|
gptkbp:product
|
recombinant DNA
|
|
gptkbp:proteinBinding
|
>98%
|
|
gptkbp:PubChem_CID
|
16132451
CHEMBL1201587
|
|
gptkbp:riskFactor
|
gptkb:lipodystrophy
hypokalemia
allergic reactions
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
gptkb:hypoglycemia
weight gain
injection site reactions
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:storage
|
2–8°C (refrigerated)
|
|
gptkbp:structureModification
|
myristic acid attached to B29 lysine
|
|
gptkbp:synonym
|
gptkb:NN304
|
|
gptkbp:UNII
|
GFX7QIS1II
|
|
gptkbp:usedFor
|
gptkb:type_2_diabetes
type 1 diabetes
|
|
gptkbp:bfsParent
|
gptkb:Insulin
|
|
gptkbp:bfsLayer
|
8
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Insulin detemir
|